Trevogrumab
REGN1033 · Anti-myostatin antibody
Popular for:Myostatin blocker, anti-muscle-loss for GLP-1 users, Regeneron antibody
1
Registered Trials
0
Trial Publications
2
PubMed References
Phase II
Evidence Level
Overview
Trevogrumab is a monoclonal antibody developed by Regeneron Pharmaceuticals that blocks myostatin (GDF-8), the protein that limits muscle growth. The short version: people usually care about it for myostatin blocker, anti-muscle-loss for glp-1 users, regeneron antibody, but the strength of the evidence depends heavily on indication and study type.
Trevogrumab is a monoclonal antibody developed by Regeneron Pharmaceuticals that blocks myostatin (GDF-8), the protein that limits muscle growth. It has gained significant attention in the peptide/biohacking community because Phase II trials showed it could preserve approximately half of the muscle mass normally lost during rapid GLP-1-mediated weight loss.
This is potentially transformative for the GLP-1 weight loss market. One of the biggest concerns with semaglutide and tirzepatide is that 25-40% of weight lost is lean mass (muscle), not just fat. Trevogrumab combined with a GLP-1 could create a 'lose fat, keep muscle' protocol — the holy grail of body composition.
Research Snapshot
What the evidence says
Phase IITrevogrumab currently shows 1 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 2 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 1 registered trials are tracked from ClinicalTrials.gov intervention records.
- 0 PubMed clinical-trial publications are indexed.
- 0 PubMed randomized controlled trial publications are indexed.
- 2 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Trevogrumab binds to circulating myostatin and prevents it from activating its receptor (ActRIIB) on muscle cells.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
1
Registered Trials
0
Trial Publications
0
RCT Publications
2
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
1
Registered trials
0
Trial publications
0
RCT publications
2
PubMed references
2
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
Trevogrumab
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceInvestigational — Phase II completed (Regeneron). Not available outside clinical trials. Represents next frontier of GLP-1 combination therapy. Regulatory timeline unclear.
Key PubMed References
Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.
Aimelet V, Holst JJ · Diabetes, obesity & metabolism · 2026
PMID: 41178728The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Stefanakis K, Kokkorakis M, Mantzoros CS · Metabolism: clinical and experimental · 2024
PMID: 39481534Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for Trevogrumab yet.
Side Effects & Safety
- Injection site reactions - Potential for tendon/joint issues from rapid muscle growth - Diarrhea (reported in some trial participants) - Full safety profile not yet established - Monoclonal antibody — potential for immune reactions
Known Interactions
No curated interaction entry is live for Trevogrumab yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.